EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model

Manuel Saldivia iD, Rajiv S Jumani iD, Bryanna Thomas, Grace M Baxley iD, Jayant Sancheti, Domenico Bullara, Jean-Rene Galarneau, Harry Cheung, Yen-Liang Chen iD, Reginara Souza DeAsis, Debjani Patra, Olivier René und 21 weitere

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2620085123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Manuel Saldivia und 32 weiteren Autor:innen. Beteiligte Einrichtung: Global Health, Biomedical Research, Novartis, Emeryville, CA 94608. Hauptthemen laut MEDLINE: Chagas Disease, Trypanosoma cruzi, Topoisomerase II Inhibitors, Triazoles. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chagas disease is a neglected disease that affects millions of people from the Latin American region. Current nitroheterocyclic therapies suffer from long treatment duration and safety-related treatment discontinuations. A safe, short course therapy would significantly benefit Chagas patients. Here, we report the comprehensive biological, structural, pharmacodynamic, and pharmacokinetic characterization of IID432, an optimized cyanotriazole with superior potency, favorable pharmacokinetics, and improved safety profile compared to the lead compound CT1. IID432 is a fast-acting, parasite-selective topoisomerase II poison that achieves sterile cure after a single oral dose in a murine model of chronic Trypanosoma cruzi infection. Mechanistically, IID432 stabilizes the parasite TcTopoII-DNA cleavage complex by covalently engaging a parasite-specific cysteine (Cys477), thereby conferring selectivity over the human TOP2A. IID432 displays favorable oral pharmacokinetics, with no off-target activity on human topoisomerases. Brief exposure of IID432 rapidly induces parasite-specific DNA damage and produces sterilizing activity in vitro and in vivo without recrudescence. Together, these findings identify IID432 as a first-in-class, parasite-selective covalent topoisomerase poison with a potential to significantly shorten treatment duration for T. cruzi infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chagas DiseaseTrypanosoma cruziTopoisomerase II InhibitorsTriazolesAnimalsMiceDisease Models, AnimalHumansDNA Topoisomerases, Type IIChronic Disease

Stichwörter der Autor:innen

Chagas diseasedrug discoverykinetoplastidpharmacologytopoisomerase

Substanzen

Topoisomerase II InhibitorsDNA Topoisomerases, Type IITriazoles

Autor:innen und Institutionen

  • Global Health, Biomedical Research, Novartis, Emeryville, CA 94608.
  • Pharmacokinetic Sciences, Novartis Healthcare Private Limited, Hyderabad 500081, India.
  • Modeling and Simulation, Biomedical Research, Novartis, Cambridge, MA 02139.
  • Preclinical Safety, Biomedical Research, Novartis, Cambridge, MA 02139.
  • Global Discovery Chemistry, Biomedical Research, Novartis Pharma AG, Emeryville, CA 94608.
  • Molecular Discovery Science, Biomedical Research, Novartis, Emeryville, CA 94608.

ORCID-Profile: Manuel Saldivia, Rajiv S Jumani, Grace M Baxley, Yen-Liang Chen, Jonas Noeske, Andreas D Schenk, Catherine Luu, Amanda Fortes Francisco, Johanne Blais, John M Kelly, Ujjini H Manjunatha, Srinivasa P S Rao

Förderung

  • Wellcome Trust

Zitieren

APA

Saldivia, M., Jumani, R. S., Thomas, B., Baxley, G. M., Sancheti, J., Bullara, D., Galarneau, J. R., Cheung, H., Chen, Y. L., DeAsis, R. S., Patra, D., René, O., Noeske, J., Schenk, A. D., Deniston, C., Thakore, S., Luu, C., Wartchow, C., Koester, D. C., …, & Rao, S. P. S. (2026). IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2620085123

Vancouver

Saldivia M, Jumani RS, Thomas B, Baxley GM, Sancheti J, Bullara D, et al. IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2620085123

BibTeX
@article{Saldivia2026,
  author = {Saldivia, Manuel and Jumani, Rajiv S and Thomas, Bryanna and Baxley, Grace M and Sancheti, Jayant and Bullara, Domenico and Galarneau, Jean-Rene and Cheung, Harry and Chen, Yen-Liang and DeAsis, Reginara Souza and Patra, Debjani and René, Olivier and Noeske, Jonas and Schenk, Andreas D and Deniston, Colin and Thakore, Samarth and Luu, Catherine and Wartchow, Charles and Koester, Dennis C and Francisco, Amanda Fortes and Blais, Johanne and Jiricek, Jan and Hollingsworth, Scott A and Gable, Jonathan E and Kelly, John M and Hochberg, Natasha and Knutson, Charlie G and Lakshminarayana, Suresh B and Sarko, Christopher and Manjunatha, Ujjini H and Osborne, Colin S and Diagana, Thierry T and Rao, Srinivasa P S},
  title = {IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2620085123}
}
Kostenlos starten →